February 2026—Octave Bioscience is collaborating with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity test accessible through Quest’s nationwide specimen-collection network. Providers that order the test from Octave will be able to refer patients with a test requisition to one of Quest’s 7,000 patient service centers and in-office phlebotomists across the United States.
The Octave MSDA test uses a blood test to measure 18 validated protein biomarkers. It reports a multiple sclerosis disease activity score, providing clinicians with data to support and inform treatment decisions, including whether to initiate, discontinue, or switch a drug therapy. The test is reimbursed by multiple payers and supported by a patient affordability program.